Scientific Sessions 2024  /  Stroke Council Award and Keynote Lecture  /  Atrial Cardiopathy and Cryptogenic Stroke
Logo

American Heart Association

  2
  0

Final ID:

Atrial Cardiopathy and Cryptogenic Stroke

  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
    • Author Disclosures:
    Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Stroke Council Award and Keynote Lecture

Monday, 11/18/2024 , 08:00AM - 09:15AM

Abstract Oral Session

More abstracts on this topic:
Cardiovascular outcomes with Glucagon-like Peptide-1 receptor agonists and Sodium-glucose Cotransporter-2 Inhibitors in patients with ischemic stroke in the community

Sheffeh Mohammad Ali, Estrada Magana Andres, Medina-inojosa Jose, Ortega Aviles Laura, Bianchettin Rosana, Medina-inojosa Betsy, Klaas James, Brown Robert, Lopez-jimenez Francisco

Neuro-specific biomarkers for risk assessment of ischemic stroke and death in patients with atrial fibrillation not receiving oral anticoagulation

Aulin Julia, Sjolin Karl, Lindback Johan, Benz Alexander, Eikelboom John, Oldgren Jonas, Wallentin Lars, Burman Joachim

More abstracts from these authors:
The Next Generation of Clinical Trials in Stroke Prevention: Crossing Borders

Kelly Peter, Kamel Hooman

The Trouble with ESUS: What do the studies tell us? Where do we do from here?

Kamel Hooman, Messe Steven

You have to be authorized to contact abstract author. Please, Login
Not Available